免疫チェックポイント阻害薬および重粒子線治療を施行した，口腔粘膜悪性黒色腫例

DOI Web Site Web Site 参考文献4件

書誌事項

タイトル別名
  • A Case of Oral Mucosal Malignant Melanoma Treated with an Immune Checkpoint Inhibitor and Carbon-Ion Radiotherapy
  • メンエキ チェックポイント ソガイヤク オヨビ ジュウ リュウシセン チリョウ オ シコウ シタ,コウコウ ネンマク アクセイ コクショク シュレイ

この論文をさがす

抄録

<p>Mucosal malignant melanoma is a fast-growing and difficult-to-control disease. New treatments, for example, carbon-ion radiotherapy and immune checkpoint inhibitors have been developed and appropriate treatment strategies including these treatments may need to be considered.</p><p>Herein, we report a case of oral mucosal melanoma with multiple cervical lymph node metastases treated with an immune checkpoint inhibitor and carbon ion radiotherapy.</p><p>The patient was a 50-year-old woman diagnosed as having malignant melanoma of the mandibular gingiva with left cervical lymph node metastasis. She received four courses of nivolumab therapy before carbon-ion radiotherapy. The metastatic lymph node enlarged until immediately after the second course of nivolumab, however, thereafter, a tendency towards shrinkage was observed. However, the lymphadenopathy persisted even after carbon-ion radiotherapy, therefore, the patient received two courses of combined nivolumab and ipilimumab therapy. However, the treatment had to be discontinued before the third course because of the development of Grade 4 liver dysfunction. The liver damage improved with steroid pulse therapy and the metastatic lymph nodes continued to shrink.</p><p>In this report, we also review the data of 23 cases of mucosal malignant melanoma who received carbon-ion radiotherapy from 2017 to 2020 at the Kanagawa Cancer Center and discuss their outcomes. Of the 23, 19 cases (87%) developed metastasis after carbon-ion radiotherapy, including distant metastasis in 12 cases (60%). For cases of advanced mucosal malignant melanoma, we believe that an effective and safe combination of topical and systemic treatment is needed.</p>

収録刊行物

参考文献 (4)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ